Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

ISO 9001 2026: What You Need to Know

The ISO 9001 standard has long been the cornerstone of quality management systems across industries. With over one million certified organizations worldwide, ISO 9001 continues to shape how businesses ensure customer satisfaction, manage risk, and improve operational performance.

Nearly a decade after the release of ISO 9001:2015, the next major revision—ISO 9001:2026—is in development. As of mid-2025, the second committee draft (CD2) has been completed, and a Draft International Standard (DIS) is expected in the second half of the year. The final publication is anticipated for late 2026.

This article explores the key elements of the draft version of ISO 9001:2026, what’s likely to change, and how organizations can start preparing now.

Why a New Revision?

The ISO 9001:2015 standard introduced risk-based thinking, process approaches, and a high-level structure (HLS) to harmonize with other ISO standards. While it brought clarity and consistency, rapid developments in digital transformation, climate responsibility, and organizational resilience have prompted the need for further updates.

The new revision aims to reflect:

  • The widespread use of digital technologies in QMS

  • Increased expectations for sustainability and ESG integration

  • Stronger emphasis on data integrity, automation, and remote management

  • Lessons learned from global events like the COVID-19 pandemic and supply chain disruptions

What Are the Key Draft Changes in ISO 9001:2026?

The ISO/TC 176/SC 2 working group is still finalizing many of the details, but several key themes have emerged in the draft documents:

1. Digital Integration and Data Systems

One of the most notable changes in ISO 9001:2026 is the recognition of digital and automated systems within quality management. While ISO 9001:2015 was relatively silent on digital tools, the 2026 draft makes it clear that software-driven processes, AI applications, and validated systems must be considered in the context of control, monitoring, and improvement.

For example, clause revisions are expected to:

  • Require controls for digitally captured data

  • Emphasize the validation and verification of digital QMS tools

  • Incorporate cybersecurity and data integrity aspects relevant to quality

This is particularly important for industries like pharmaceuticals and medical devices, where computerized systems are deeply embedded in compliance.

Achieve operational excellence by building a strong foundation of equipment qualification documentation and protocols.

2. Sustainability and ESG Focus

ISO 9001:2026 aligns more closely with sustainability and Environmental, Social, and Governance (ESG) expectations. This doesn’t mean it becomes an ESG standard, but it requires organizations to:

  • Consider environmental impact as part of context and risk analysis

  • Align quality objectives with broader corporate responsibility frameworks

  • Show leadership engagement in ESG-relevant goals

Organizations will need to document how quality management supports sustainable business practices, especially in supply chain and product development.

3. Structural Realignment: From HLS to Harmonized Structure

The 2026 version moves from the High-Level Structure (HLS) to the Harmonized Structure (HS) introduced by ISO in recent years. This change will make ISO 9001 more consistent with other standards like ISO 14001 (environmental) and ISO 45001 (occupational health and safety).

While the main clause numbers (4 to 10) will remain largely unchanged, the language and guidance will be more aligned across disciplines, making multi-standard integrations easier.

4. Resilience, Risk, and Quality Culture

ISO 9001:2015 introduced risk-based thinking. ISO 9001:2026 builds on that with clearer guidance on:

  • Distinguishing between risk and opportunity

  • Building organizational resilience through robust planning and monitoring

  • Promoting a quality culture that goes beyond compliance

This reflects growing demand from regulators and customers for proactive risk management and cultural maturity in organizations.

5. Expanded Annex A: Guidance on Application

Annex A in the draft standard is being significantly expanded. Rather than only clarifying requirements, it now includes practical guidance for implementation, similar to an embedded best practice guide.

This makes the standard more accessible, especially for smaller organizations or those implementing ISO 9001 for the first time.

Zamann Pharma Support provides guidance for optimizing Quality Management Systems (QMS) for regulatory compliance.

Quality Management Systems Landscape – Implementation or Improvement

Zamann Pharma Support offers guidance for developing effective knowledge management strategies across organizations.

Knowledge Management – Strategic Consultancy

Document tracking system used for monitoring internal audit activities.

Periodical Internal Audits – Routine Support

Timeline and Next Steps

Here is the expected timeline for ISO 9001:2026:

MilestoneExpected Date
Committee Draft 2 (CD2)Q1 2025
Draft International Standard (DIS)Q3 2025
Final Draft International Standard (FDIS)Mid 2026
Publication of ISO 9001:2026Q4 2026
Transition PeriodLikely 2–3 years

Organizations are advised to begin preparing now by:

  1. Reviewing current QMS alignment with digital and ESG trends

  2. Training internal auditors and QMRs on upcoming changes

  3. Conducting gap assessments using available committee guidance

  4. Following updates from ISO/TC 176 and national standards bodies

Conclusion

ISO 9001:2026 is not a reinvention but a timely modernization. It aims to ensure that quality management systems are relevant, robust, and resilient in the face of digital disruption, global complexity, and increased regulatory expectations.

For companies that want to remain competitive, compliant, and forward-thinking, the upcoming revision is an opportunity—not a burden. Now is the time to anticipate, evaluate, and act.

References

Picture of Alireza Zarei
Alireza Zarei

Alireza Zarei is the founder and CEO of Zamann Pharma Support GmbH in Germany. He pairs 20 years in GMP—beginning in a lab in 2005—with front-line global project delivery for companies such as Boehringer Ingelheim, Roche, BioNTech, Takeda, Fresenius Medical Care, Biotest, ratiopharm and others. He focuses on innovative validation and qualification procedures, master data management strategies, end-to-end LIMS implementation and care, with pragmatic advice on general Quality Management topics and management level OpEx consulting. Together with his team he also created Pharmuni.com as the leading GMP learning platform in the industry.